

April 29, 2021**Contents**

Clinical Profile: New Problems.....	2
Lab Analyte and Panel Additions and Updates.....	2
Medications	3
Additions.....	3
Updates.....	3
Regimens.....	4
Updates.....	4
Akyntzeo.....	4
Cisplatin Infusion Length.....	4
Rituximab	4
Regimen Updates.....	4
Additions.....	5
Value Pathway Regimens.....	5
Renamed Regimens	6
Research.....	6
Updates.....	6
Data Migration	6
Akyntzeo.....	6
Regimen Additions.....	7
Billing: HCPCS Code Updates	8

Clinical Profile: New Problems

Sacroccocygeal teratoma is available under Problems sand appears on the Charge Capture Report (CCR). Its ICD10 Code is **D48.0 - Neoplasm of uncertain behavior of bone and articular cartilage**.

Lab Analyte and Panel Additions and Updates

- 1p19q FISH panel
- 5' Nucleotidase
- 5' Nucleotidase panel
- Abnormal band 2 concentration, mg/dL
- Abnormal band concentration, mg/dL
- Acid fast bacteria culture and smear panel
- Acid fast bacteria culture and smear panel
- AFB final culture report
- AFB preliminary culture report
- Aldos/Renin ratio
- ALK (2p23) FISH panel
- Alpha-1 antitrypsin, serum
- Alpha-1-antitrypsin phenotype
- Alpha-1-antitrypsin phenotype panel
- Amphetamines confirmation, blood
- Appearance, pleural fluid
- Atopobium vaginae
- B cell panel
- B cell panel assay description
- B cell panel interpretation
- Beta globulin, %
- BRCAVantage method and limitations
- Buspirone panel, serum or plasma
- Buspirone, serum or plasma
- BVAB 2
- CBDI result grid
- Cell count and differential panel, pleural fluid
- c-KIT Mutation analysis background
- c-KIT Mutation analysis director review
- c-KIT Mutation analysis disclaimer
- c-KIT Mutation analysis methodology
- c-KIT Mutation analysis reference
- c-KIT Mutation analysis result
- c-KIT Mutation, liquid tumor panel
- c-MET amplification FISH
- c-Met by FISH panel
- Color, pleural fluid
- Complement factor I, mcg/mL
- Copper, free panel
- Copper, free, mcg/L
- Cortisol free dialysis, LCMS panel
- Cortisol, free dialysis, LCMS, ug/dL
- COVID-19 Non-PUI Ag panel
- COVID-19 Non-PUI Ag, qual
- C-Peptide, ultrasensitive, ES panel
- C-Peptide, ultrasensitive, ES, ng/mL
- Cytokine panel 13, serum
- Donor, CMV ab, total panel
- Donor, Hepatitis B core ab, total panel
- Donor, Hepatitis B surface antigen panel
- Donor, Hepatitis C Ab panel
- Donor, Hepatitis C core ab, total panel
- Donor, HIV 1/HBV/HCV/NAT Procleix(R) w/ reflex panel
- Donor, HIV ab screen panel
- Donor, HTLV I/II antibody screen panel
- Donor, syphilis IgG Ab panel
- EBV antibody panel interpretation
- FISH Oncology cell analyzed
- FISH Oncology cells counted
- FISH Oncology director review
- FISH Oncology interpretation
- FISH Oncology panel
- FISH Oncology result
- FISH Oncology specimen type
- FusionSEQ panel
- FusionSEQ result
- Hem collection
- HPV Aptima, qual
- HPV, Aptima high 16/18,45 panel
- Interferon gamma, serum
- Interleukin 1 beta, serum
- Interleukin-10, pg/mL
- Interleukin-12, pg/mL
- Interleukin-13, pg/mL
- Interleukin-17, pg/mL

- Interleukin-2 receptor soluble
- Interleukin-2, pg/mL
- Interleukin-4, pg/mL
- Interleukin-5, pg/mL
- Interleukin-6, pg/mL
- Interleukin-8, pg/mL
- Lactate Pyruvate ratio
- LDH, pleural fluid, IU/L
- Liver-kidney microsomal (LKM) antibody panel
- LKM-1 Antibody (IgG)
- M. avium DNA, qual
- M. avium-intracellulare DNA qualitative RT-PCR panel
- M. avium-intracellulare specimen source
- M. intracellulare DNA, qual
- MDA, blood, ng/mL
- MDEA, blood, ng/mL
- MDMA, blood, ng/mL
- Measles Ab, IgG, AU/mL
- Measles, Mumps, Rubella (MMR) IgG panel, qual
- Megasphaera 1
- MGMT-Me panel
- Monocytes, pleural fluid
- Mumps Ab, IgG, AU/mL
- Myeloperoxidase (MPO), pmol/L
- Neutrophils, pleural fluid
- NuSwab Select, bacterial vaginosis, NAA
- P16 panel
- Pyruvate CSF
- Pyruvate CSF panel
- Quantiferon TB gold plus
- Quantiferon TB1 Ag value
- Quantiferon TB2 Ag value
- RBC count, pleural fluid
- RNA polymerase III IgG Abs
- RNA polymerase III IgG Abs panel
- Rubella Ab, IgG, Index
- S. pneumoniae serotype interpretation
- SARS-CoV-2 Ab, Nucleocapsid
- SARS-CoV-2 Ab, Nucleocapsid panel
- Tempus Kits
- TMB result
- Troponin T(highly sensitive) panel
- Troponin T(highly sensitive), ng/L
- Tumor mutation burden panel
- Tumor mutation burden result
- Tumor necrosis factor, alpha, serum
- UPE comment
- WBC count, pleural fluid

Medications

Additions

- 68Ga-PSMA-11 invest IV
- AL101 invest IV
- BAY 43-9006 invest or placebo Oral
- CEP-37250/KHK2804 invest IV
- Dato-DXd (datopotamab deruxtenca; DS-1062a) invest
- ERAS-007 invest Oral
- EU101 invest IV
- Florbetaben f-18 IV
- Florbetapir f-18 IV
- Fluciclovine f-18 IV
- Fluorodeoxyglucose f-18 IV
- Flutemetamol f-18 IV
- Impact Advanced Recovery Oral Liquid
- Panitumumab invest IV
- Syringe with needle 1 mL 25 gauge x 1"
- Syringe with needle 3 mL 21 gauge x 1 1/2"
- TCID50 invest Intratumoral
- TPST-1120 invest Oral
- Trametinib invest Oral
- VSV-IFN(beta)-NIS 3x10e9
- XB2001 invest IV

Updates

- **Albumin IV 5%** now includes a billing amount of **12.5 grams**
- Quick Sig Picks for **Acetaminophen Oral** now include:

- **650 mg orally once**
- **500 mg orally once**
- **325 mg orally once**
- For **AGEN2034 invest IV**, **Unit mg/kg** is now available
- Quick Sig Picks for **Diphenhydramine Oral** now include:
 - **25 mg orally once**
 - **50 mg orally once**
- For **ORIC-101 invest Oral**, **Form ORIC-101 invest 80 mg Tablet** is now available
- All Quick Sig Picks with "tabs" for **Zofran (Ondansetron Oral)** are retired

Regimens

This section does not include clinical trial regimens.

Updates

Akynzeo

Stock has run out on **Fosnetupitant-Palonosetron IV 235 mg-0.25 mg** with **NDC 69639-0102-01 (GCN 78376)**.

To ensure iKnowMed and Lynx remain in alignment, regimens containing **Akynzeo** are updated with the most current NDC available. The new medication name is **Fosnetupitant-Palonosetron IV 235 mg-0.25 mg/20 mL** with **NDC 69639-0105-01 (GCN 81424)**.

Cisplatin Infusion Length

To align with standard clinical practice, optimize infusion chair time, and save patients time, the Collaborative Care Committee voted to change the **Cisplatin** infusion length to "1-2 hours" from the historical standard of "over at least 1 hour but no faster than 1 mg/min".

Rituximab

Rituximab Rapid Infusion Protocol was recently updated to allow transition to rapid infusion after **1 dose of Rituximab** at the standard rate, rather than the 2+ doses previously required for monotherapy and select regimens. All regimen templates containing Rituximab reflect this change.

Regimen Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Bladder Cancer
- Breast Cancer
- Colon Cancer
- Esophageal Cancer (Parent)
- Gastric Cancer
- Leukemia, Acute Myeloid (AML)
- Leukemia, Chronic Lymphocytic (CLL)
- Leukemia, Hairy Cell
- Lung Cancer, Non-small Cell (NSCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Multiple Myeloma (MM)
- Prostate Cancer
- Rectal Cancer
- Renal Cell Carcinoma (RCC)
- Renal Pelvis and Ureter Cancer
- Urethral Cancer
- Uterine Cancer (Parent)

Additions

The following regimens are now available for ordering in the Regimen Library.

- Daratumumab SQ + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q21D (Part 1 of 2)
- Daratumumab SQ + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q28D (Part 2 of 2: Daratumumab SQ + Lenalidomide Maintenance)
- Darolutamide + Bicalutamide + Goserelin Q3M
- Darolutamide + Bicalutamide + Leuprolide Q3M
- Isatuximab-irfc + Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D
- Tivozanib Q28D

Value Pathway Regimens

The following Value Pathway regimens were added, removed or updated:

- Daratumumab SQ + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q21D (Part 1 of 2)
- Daratumumab SQ + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q28D (Part 2 of 2: Daratumumab SQ + Lenalidomide Maintenance)
- Darolutamide + Bicalutamide + Goserelin Q3M
- Darolutamide + Bicalutamide + Leuprolide Q3M
- Fam-Trastuzumab Deruxtecan-nxki Q21D
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) Q14D
- Isatuximab-irfc + Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D
- Pembrolizumab + Lenvatinib Q21D
- Pembrolizumab Q21D (Flat Dose)
- Pembrolizumab Q42D (Dose Banding)
- Pembrolizumab Q42D (Flat Dose)
- Ribociclib D1-21 + Tamoxifen + Goserelin Q28D
- Ribociclib D1-21 + Tamoxifen + Leuprolide Q28D
- Ribociclib D1-21 + Tamoxifen Q28D
- Tivozanib Q28D

Renamed Regimens

Previous Name	New Name
Cladribine D1-5 Q28D	Cladribine D1-5 Q28D (CLL, NHL)
Cladribine CIV D1-7 Q7D	Cladribine CIV D1-7
Daratumumab + Bortezomib + Dexamethasone Q21D (Part 1 of 2)	Daratumumab IV + Bortezomib + Dexamethasone Q21D (Part 1 of 2)
Daratumumab + Bortezomib + Dexamethasone Q21D (Part 1 of 2: C1 Split Dosing)	Daratumumab IV + Bortezomib + Dexamethasone Q21D (Part 1 of 2: C1 Split Dosing)
Daratumumab + Lenalidomide + Dexamethasone Q28D	Daratumumab IV + Lenalidomide + Dexamethasone Q28D
Daratumumab + Lenalidomide + Dexamethasone Q28D (C1 Split Dosing)	Daratumumab IV + Lenalidomide + Dexamethasone Q28D (C1 Split Dosing)
Daratumumab + Pomalidomide + Dexamethasone Q28D	Daratumumab IV + Pomalidomide + Dexamethasone Q28D
Daratumumab + Pomalidomide + Dexamethasone Q28D (C1 Split Dosing)	Daratumumab IV + Pomalidomide + Dexamethasone Q28D (C1 Split Dosing)
Fam-Trastuzumab Deruxtecan-nxki Q21D	Fam-Trastuzumab Deruxtecan-nxki Q21D (Breast)
Fam-Trastuzumab Deruxtecan-nxki Q21D (Colon, Rectal, Gastric, NSCLC)	Fam-Trastuzumab Deruxtecan-nxki Q21D
Pemetrexed + Cisplatin Q21D + XRT	Pemetrexed + Cisplatin + XRT Q21D

Research

Updates

Data Migration

To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.

Akynzeo

Stock has run out on **Fosnetupitant-Palonosetron IV 235 mg-0.25 mg** with **NDC 69639-0102-01 (GCN 78376)**.

To ensure iKnowMed and Lynx remain in alignment, regimens containing **Akynzeo** are updated with the most current NDC available. The new medication name is **Fosnetupitant-Palonosetron IV 235 mg-0.25 mg/20 mL** with **NDC 69639-0105-01 (GCN 81424)**.

Regimen Additions

The USOR Clinical Trials listed in the table below are updated:

	Updated Reference Information			
		Updated Drug Service Order Information		
			Updated Regimen Instructions	
				Other Changes
USOR 17087	X			
USOR 17194		X		
USOR 18187		X		
USOR 19001	X	X	X	
USOR 19024	X	X	X	The following regimen is now available for ordering: USOR 19024 Phase 2 Part B AMG 510 Monotherapy (PO; Daily) The following regimens are no longer available for ordering: USOR 19024 Phase 1 AMG 510 Monotherapy (PO; Daily) USOR 19024 Phase 1 AMG 510 Monotherapy (PO; BID) USOR 19024 Phase 2 AMG 510 Monotherapy (PO; Daily)
USOR 19081	X	X	X	
USOR 19113	X	X	X	
USOR 19205	X	X	X	The following regimens are now available for ordering: USOR 19205 Phase 3 Arm A Ublituximab + Umbralisib (Cycle 1-3) USOR 19205 Phase 3 Arm A Ublituximab + Umbralisib + Venetoclax (Cycle 4) USOR 19205 Phase 3 Arm A Ublituximab + Umbralisib + Venetoclax (Cycles 5-6) USOR 19205 Phase 3 Arm A Ublituximab + Umbralisib + Venetoclax (Cycles 7-24) USOR 19205 Phase 3 Arm B Ublituximab + Umbralisib (Cycle 1-6) USOR 19205 Phase 3 Arm B Ublituximab + Umbralisib (Cycle 7+)
USOR 20155	X	X	X	
USOR 20208	X			
USOR 20227	X			
USOR 20248	X			
USOR 20307	X			
USOR 20308	X			

	Updated Reference Information			
		Updated Drug Service Order Information		
			Updated Regimen Instructions	
				Other Changes
USOR 20309	X			
USOR 20310	X			
USOR 20358	X	X	X	The following regimens are now available for ordering: USOR 20358 Venetoclax Bridging Therapy (Venetoclax Combination Cohort) USOR 20358 Lymphodepleting Chemotherapy: Fludarabine D1-3 + Cyclophosphamide D1-3 USOR 20358 JCAR017 (Lisocabtagene Maraleucel) + Venetoclax
USOR 20384	X			
USOR 20386	X			
USOR 20387	X			
USOR 20388	X			

Billing: HCPCS Code Updates

Medication	HCPCS Code
Copper Cu-64 Dotatate IV	A9592 per 1 mCi
Diph, Pertus(Acel), Tet Ped (PF) IM	90700 per 0.5 mL
Evinacumab-dgnb IV	J3590 per 1200 mg
Florbetaben f-18 IV	Q9983 per 8.1 mCi
Florbetapir f-18 IV	A9586 per 10 mCi
Fluciclovine F 18 IV	A9588 per 1 mCi
Fluorodeoxyglucose f-18 IV	A9552 per 45 mCi
Flutemetamol f-18 IV	Q9982 per 5 mCi
Gallium-67 Citrate IV 74 MBq/mL (2 mCi/mL)	A9556 per 1 mCi
Idecabtagene vicleucel IV	J3590 per 300x 10e6 CARpos viable T cells J3590 per 450x 10e6 CARpos viable T cells J3590 per 460x 10e6 CARpos viable T cells

Medication	HCPSC Code
Influenza Virus Vaccine (Southern Hemisphere) IM Quad-Split (6 months & older)	90688 per 0.5 mL
Influenza Virus Vaccine (Southern Hemisphere) (PF) IM Quad-Split (6 months & older)	90686 per 0.5 mL
Lisocabtagene Maraleucel (CD8) IV (1 of 2)	J3590 per 40 x 10e6 CARpos viable T cells
Lisocabtagene Maraleucel (CD4) IV (2 of 2)	J3590 per 40 x 10e6 CARpos viable T cells
Radium Ra 223 Dichloride IV	A9606 per 1 mCi
Tisagenlecleucel IV	Q2042 per 0.8 x 10e8 CARpos viable T cells